Today, Ocrevus (ocrelizumab) was granted a licence by the European Commission to treat people with two forms of multiple sclerosis (MS) including the first and only licence for primary progressive MS (PPMS), the most debilitating form of the disease, in which disability increases from the outset.
Ocrevus, from Switzerland’s Roche (ROG: SIX), best known as the world’s largest cancer drugs maker, has also been licensed for relapsing MS (RMS), providing a new treatment option for these patients. The full approval comes after a positive opinion last November from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Roche’s shares were up 1% at 246.95 Swiss francs in early trading this morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze